0. DOCID:31048 SCORE: 0.00265792404514176
DOCNO: 15993065
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: chemical synthesis
QUALIFIER: chemistry
QUALIFIER: chemical synthesis
AUTHOR: Timothy A Blizzard TA
AUTHOR: Frank DiNinno F
AUTHOR: Helen Y Chen HY
AUTHOR: Seongkon Kim S
AUTHOR: Jane Y Wu JY
AUTHOR: Wanda Chan W
AUTHOR: Elizabeth T Birzin ET
AUTHOR: Yi Tien Yang YT
AUTHOR: Lee-Yuh Pai LY
AUTHOR: Edward C Hayes EC
AUTHOR: Carolyn A DaSilva CA
AUTHOR: Susan P Rohrer SP
AUTHOR: James M Schaeffer JM
AUTHOR: Milton L Hammond ML
AFFILIATION: Merck Research Laboratories, RY800-B116, P.O. Box 2000, Rahway, NJ 07065, USA. tim.blizzard@merck.com
PUBTYPE: Journal Article
JOURNALTITLE: Bioorganic & medicinal chemistry letters.
COUNTRY: England
TITLE: Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain.
PUBDATE: 20050901
An optimized side chain for dihydrobenzoxathiin SERAMs was discovered and attached to four dihydrobenzoxathiin platforms. The novel SERAMs show exceptional estrogen antagonist activity in uterine tissue and an MCF-7 breast cancer cell assay.


1. DOCID:31137 SCORE: 0.00265792312014053
DOCNO: 16143160
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: analogs & derivatives
QUALIFIER: drug therapy
AUTHOR: Howard A Burris HA
AFFILIATION: The Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville, USA. hburris@tnonc.com
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Seminars in oncology.
COUNTRY: United States
TITLE: Recent updates on the role of chemotherapy in pancreatic cancer.
PUBDATE: 20050801
Single-agent gemcitabine remains the standard treatment for advanced pancreatic cancer. Recent phase III trials have failed to show improvements in survival using gemcitabine in combination with other chemotherapeutic agents, although the gemcitabine/oxaliplatin combination has shown some promise. The combination of gemcitabine with erlotinib was associated with a significant prolongation of survival. Promising results in a phase II trial of gemcitabine in combination with bevacizumab have led to a randomized comparative trial of the combination. Potential combinations with other biologic agents are being investigated.


2. DOCID:29408 SCORE: 0.00263601839814681
DOCNO: 16281265
OWNER: NLM
STATUS: In-Process
AUTHOR: Philippe Vignal P
PUBTYPE: Journal Article
JOURNALTITLE: Journal of clinical ultrasound : JCU.
COUNTRY: United States
TITLE: Sonographic appearance of a carcinoma developed in ectopic axillary breast tissue.
PUBDATE: 20051201
Primary breast cancer of ectopic axillary breast tissue is almost never diagnosed preoperatively. When not accompanied by nipple-areolar complex, the mass is often believed to be a lipoma, an enlarged lymph node, or a skin lesion such as a sebaceous cyst or hydradenitis suppurativa. When an axillary mass is found, a percutaneous needle biopsy is mandatory to rule out the diagnosis of cancer in ectopic breast tissue. We describe the sonographic findings of a case of ductal carcinoma in axillary ectopic breast tissue.


3. DOCID:31262 SCORE: 0.00250075944347158
DOCNO: 15830143
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Quality of Life
DESCRIPTOR: Questionnaires
QUALIFIER: complications
QUALIFIER: pathology
AUTHOR: Kathleen J Yost KJ
AUTHOR: Susan E Yount SE
AUTHOR: David T Eton DT
AUTHOR: Cheryl Silberman C
AUTHOR: Anne Broughton-Heyes A
AUTHOR: David Cella D
AFFILIATION: Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare Research Institute, 1001 University Place, Suite 100, Evanston, IL 60201, USA. kyost@enh.org
PUBTYPE: Journal Article
PUBTYPE: Validation Studies
JOURNALTITLE: Breast cancer research and treatment.
COUNTRY: Netherlands
TITLE: Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI).
PUBDATE: 20050401
We assessed the reliability, validity, and responsiveness to change of the 6-item Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI) in a sample of 615 metastatic breast cancer patients. The FBSI is a brief, clinically relevant, and psychometrically sound instrument that can be used to measure symptoms in patients with breast cancer.


4. DOCID:29831 SCORE: 0.0022463991025495
DOCNO: 11966724
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: epidemiology
AUTHOR: Thomas L Diepgen TL
AUTHOR: V Mahler V
AFFILIATION: Department of Clinical Social Medicine and Dermato-Epidemiology, University Hospital Heidelberg, Bergheimer Str. 58, 69115 Heidelberg, Germany. thomas.diepgen@med.uni-heidelberg.de
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: The British journal of dermatology.
COUNTRY: England
TITLE: The epidemiology of skin cancer.
PUBDATE: 20020401
Melanoma and non-melanoma (basal and squamous cell carcinoma) skin cancer (NMSC) are now the most common types of cancer in the white populations and the incidence of skin cancer has reached epidemic proportions. According to recent population-based studies from Australia the incidence rate is over 2% for basal cell carcinoma in males and 1% for squamous cell carcinoma, and there are over 50 new cases of melanoma per 100 000.


5. DOCID:28664 SCORE: 0.00216111975235806
DOCNO: 16425560
OWNER: NLM
STATUS: In-Process
AUTHOR: Wai Yip Stephen Lau WY
AUTHOR: Chun Kuen Chow CK
AFFILIATION: Division of Otorhinolaryngology, Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong.
PUBTYPE: Journal Article
JOURNALTITLE: The Annals of otology, rhinology, and laryngology.
COUNTRY: United States
TITLE: Radiation-induced petrous internal carotid artery aneurysm.
PUBDATE: 20051201
Iatrogenic internal carotid artery aneurysm is a rare complication of irradiation. There are few reported cases in the literature. A case of radiation-induced petrous internal carotid artery aneurysm in a patient with nasopharyngeal cancer treated with radiotherapy is reported. The approach to managing such an aneurysm is discussed.


6. DOCID:28586 SCORE: 0.00216111935814863
DOCNO: 16360475
OWNER: NLM
STATUS: In-Data-Review
AUTHOR: Masashi Honda M
AUTHOR: Ikuo Miyagawa I
AFFILIATION: Department of Urology, Faculty of Medicine, Tottori University, Yonago, Tottori, Japan. Honda@grape.med.tottori-u.ac.jp
PUBTYPE: Journal Article
JOURNALTITLE: Urology.
COUNTRY: United States
TITLE: Prostatic meningeal carcinomatosis with low serum level of prostate-specific antigen.
PUBDATE: 20051201
Less than 1% of patients with metastatic prostate cancer present with abnormally low serum levels of prostate-specific antigen (PSA). Furthermore, cases of prostatic metastases to the meninges with a low serum level of PSA are extremely rare. The present report describes a patient with prostatic meningeal carcinomatosis and low serum PSA levels.


7. DOCID:31949 SCORE: 0.00203820894043995
DOCNO: 11997568
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Echo-Planar Imaging
QUALIFIER: blood supply
QUALIFIER: pathology
AUTHOR: Jean-Paul Delille JP
AUTHOR: Priscilla J Slanetz PJ
AUTHOR: Eren D Yeh ED
AUTHOR: Daniel B Kopans DB
AUTHOR: Leoncio Garrido L
AFFILIATION: Department of Radiology, NMR Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
PUBTYPE: Journal Article
JOURNALTITLE: Radiology.
COUNTRY: United States
TITLE: Breast cancer: regional blood flow and blood volume measured with magnetic susceptibility-based MR imaging--initial results.
PUBDATE: 20020501
The purpose of this study was to quantify microcirculation in breast neoplasms with magnetic susceptibility-based contrast material-enhanced magnetic resonance imaging. With this imaging method for invasive cancers, the mean values of the ratios of tumor to normal blood flow and blood volume were significantly higher (P <.002) than those for benign or normal tissue. The method allows independent measurement of regional blood flow and blood volume in breast cancers.


8. DOCID:31968 SCORE: 0.00203820696295399
DOCNO: 12471873
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: surgery
QUALIFIER: surgery
AUTHOR: Cameron D Wright CD
AUTHOR: Kenneth A Kesler KA
AFFILIATION: Harvard Medical School, Section of General Thoracic Surgery, Massachusetts General Hospital, Boston, MA, USA. Wright.Cameron@mgh.harvard.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Chest surgery clinics of North America.
COUNTRY: United States
TITLE: Surgical techniques and outcomes for primary nonseminomatous germ cell tumors.
PUBDATE: 20021101
Patients with primary mediastinal nonseminomatous germ cell tumors are usually young men with large anterior mediastinal masses. The diagnosis can usually be established with measurement of serum tumor markers and a fine-needle aspiration biopsy. The mainstay of treatment is cisplatin-based chemotherapy. Resection of the residual postchemotherapy mass is usually necessary and is performed even with persistently elevated tumor markers if a clean resection is possible. The finding of necrotic tumor predicts long-term survival, whereas persistent germ cell cancer has a less favorable prognosis.


9. DOCID:31036 SCORE: 0.00195735227182248
DOCNO: 16213134
OWNER: NLM
STATUS: In-Process
AUTHOR: P K Tsantoulis PK
AUTHOR: V G Gorgoulis VG
AFFILIATION: Department of Histology and Embryology, Molecular Carcinogenesis Group, School of Medicine, University of Athens, Antaiou 53 Str, Lamprini, Ano Patissia, GR-11146, Athens, Greece.
PUBTYPE: Journal Article
JOURNALTITLE: European journal of cancer (Oxford, England : 1990)
COUNTRY: England
TITLE: Involvement of E2F transcription factor family in cancer.
PUBDATE: 20051101
The E2F family of transcription factors is a central modulator of important cellular events, including cell cycle progression, apoptosis and DNA damage response. The role of E2F family members in various human malignancies is yet unclear and may provide vital clues to the diagnosis, prognosis and therapy of cancer patients. In this review we provide a brief but concise overview of E2F function and its putative role in the most common human tumour types.


10. DOCID:31352 SCORE: 0.00195735189083872
DOCNO: 16213009
OWNER: NLM
STATUS: In-Data-Review
AUTHOR: Alan R Shaw AR
AFFILIATION: Merck Vaccine Division, West Point, PA 19486, USA.
PUBTYPE: Journal Article
JOURNALTITLE: Gynecologic oncology.
COUNTRY: United States
TITLE: Human papillomavirus vaccines in development: If they're successful in clinical trials, how will they be implemented?
PUBDATE: 20051201
INTRODUCTION.: There are some 30-40 genotypes of human papillomavirus (HPV) that cause anogenital lesions in humans, primarily cervical, vaginal, and vulvar dysplasias and cancer in women, anal dysplasias in some men, and genital warts in both sexes. METHODS.: Both GlaxoSmithKline and Merck companies are developing vaccines for the prevention of HPV infection. RESULTS.: Both vaccines stimulate an antibody response against HPV types 16 and 18; the Merck vaccine also include HPV types 6 and 11. CONCLUSIONS.: This report focuses on progress with both prophylactic vaccines and introduces strategies for global immunization.


11. DOCID:31633 SCORE: 0.00190342810897654
DOCNO: 15066230
OWNER: NLM
STATUS: In-Data-Review
AUTHOR: Alexandria T Phan AT
AUTHOR: Jaffer A Ajani JA
AFFILIATION: University of Texas MD Anderson Cancer Center, GI Medical Oncology Department, 1515 Holcombe Boulevard, Mailbox 426, Houston, TX 77030, USA. aphan@mdanderson.org E-mail: jajani@mdanderson.org
PUBTYPE: Journal Article
JOURNALTITLE: Current oncology reports.
COUNTRY: United States
TITLE: Gastric carcinoma.
PUBDATE: 20040501
Although gastric cancer is still a worldwide major public health concern, it remains relatively uncommon in the Western countries. Despite improvement in surgical morbidity and mortality, as well as significant advancement of chemotherapy and radiotherapy options, the survival for gastric cancer has not significantly improved over the past decades. In the United States, standard of care for localized resectable gastric cancer is with adjuvant chemoradiotherapy. In this article, we summarize salient randomized and phase II and III clinical trials representing current treatment for gastric cancer.


12. DOCID:28651 SCORE: 0.0016910558257251
DOCNO: 14505647
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: chemistry
QUALIFIER: chemistry
QUALIFIER: drug effects
QUALIFIER: chemistry
AUTHOR: Ahmed Kamal A
AUTHOR: G Ramesh G
AUTHOR: P Ramulu P
AUTHOR: O Srinivas O
AUTHOR: Tasneem Rehana T
AUTHOR: G Sheelu G
AFFILIATION: Division of Organic Chemistry, Indian Institute of Chemical Technology, Hyderabad 500007, India. ahmedkamal@iict.ap.nic.in
PUBTYPE: Journal Article
JOURNALTITLE: Bioorganic & medicinal chemistry letters.
COUNTRY: England
TITLE: Design and synthesis of novel chrysene-linked pyrrolo[2,1-c][1,4]-benzodiazepine hybrids as potential DNA-binding agents.
PUBDATE: 20031001
Chrysene-linked pyrrolobenzodiazepine hybrids have been prepared that possess cytotoxicity in some cancer cell lines. They also exhibit promising DNA-binding affinity and this is supported by molecular modeling studies.


13. DOCID:29322 SCORE: 0.00169063292226262
DOCNO: 12380663
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: methods
QUALIFIER: complications
QUALIFIER: drug therapy
AUTHOR: C Wilsey C
AUTHOR: N S Ashford NS
AUTHOR: S J Dolin SJ
AFFILIATION: St. Richard's Hospital, Chichester, UK.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Palliative medicine.
COUNTRY: England
TITLE: Presacral neurolytic block for relief of pain from pelvic cancer: description and use of a CT-guided lateral approach.
PUBDATE: 20020901
A CT guided lateral approach for neurolysis of the presacral plexus is described for treatment of pelvic pain due to advanced cancer. The technique was evaluated in two patients with unrelieved pelvic and perineal pain. Other neurolytic techniques used to treat pelvic pain due to advanced cancer are reviewed with a discussion of benefits and potential side effects of this technique.


14. DOCID:29260 SCORE: 0.00168467042260344
DOCNO: 12724735
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Oncogenes
QUALIFIER: genetics
QUALIFIER: therapy
AUTHOR: Dean W Felsher DW
AFFILIATION: Division of Oncology, Department of Medicine, Stanford University, 269 Campus Drive, CCSR 1105, Stanford, California 94305-5151, USA. dfelsher@stanford.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nature reviews. Cancer.
COUNTRY: England
TITLE: Cancer revoked: oncogenes as therapeutic targets.
PUBDATE: 20030501
Recent findings show that even the brief inactivation of a single oncogene might be sufficient to result in the sustained loss of a neoplastic phenotype. It is therefore possible that the targeted inactivation of oncogenes could be a specific and effective treatment for cancer. So why does oncogene inactivation cause tumour regression and will this be a generally successful approach for the treatment of human neoplasia?